Competent Cells Market Report 2025

This Competent Cells market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The competent cells market size has grown rapidly in recent years. It will grow from $2.65 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing demand for genetic cloning, increasing government funding for life sciences research, growth in the biotechnology workforce, increasing focus on rare disease research, and rise in outsourcing research activities to contract research organizations.

The competent cells market size is expected to see rapid growth in the next few years. It will grow to $4.97 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, increasing investment in biotechnology startups, increasing demand for recombinant protein production, increasing prevalence of chronic diseases, and increasing demand for industrial biotechnology solutions. Major trends in the forecast period include technological advancements, artificial intelligence, quantum computing, 5G technology, and wearable technology.

The expanding biopharmaceutical industry is expected to drive the growth of the competent cells market in the coming years. The biopharmaceutical industry focuses on the development, production, and commercialization of drugs derived from biological sources, utilizing biotechnology and molecular biology to create innovative therapies and treatments. This industry is growing due to rapid advancements in biotechnology, increasing demand for personalized medicine, and rising investments in research and development for novel therapies. Competent cells play a critical role in the biopharmaceutical industry by supporting genetic engineering, gene cloning, and protein expression, which are essential for producing recombinant proteins, therapeutic enzymes, and other biologics used in drug development. For example, in May 2024, the Pharmaceutical Research and Manufacturers of America (PhRMA), a US-based trade association, reported that the U.S. biopharmaceutical industry generated over $800 billion in direct output in 2022, contributing around 1.6% to the GDP and accounting for 17.6% of all domestic business R&D activity. Thus, the growth of the biopharmaceutical industry is driving the expansion of the competent cells market.

Key companies in the competent cells market are introducing innovative kits, such as replication competent lentivirus kits, to improve cell and gene therapies and enhance the efficiency of genetic transformation processes. Cell and gene therapies involve modifying or using cells or genes to treat or cure diseases. For instance, Bio-Rad Laboratories Inc., a US-based clinical diagnostics manufacturer, released the Vericheck ddPCR replication competent lentivirus kit and the Vericheck ddPCR replication competent AAV kit in February 2024. These kits utilize advanced droplet digital PCR (ddPCR) technology to detect and quantify replication-competent lentivirus (RCL) and adeno-associated virus (AAV) with high sensitivity and precision. This technology is vital for ensuring the safety and effectiveness of viral vectors used in therapeutic applications by detecting and eliminating potentially harmful replication-competent viruses.

In June 2024, JumpCode Genomics Inc., a US-based biotechnology company, formed a partnership with Takara Bio USA, Inc. to merge their core intellectual property (IP) for CRISPR-based targeted removal of unwanted transcripts, such as ribosomal RNAs, from next-generation sequencing (NGS) libraries. Through this collaboration, JumpCode Genomics and Takara Bio USA aim to combine their patented CRISPR-based technologies to enhance research applications, including those related to competent cells, by improving the removal of undesired sequences from biological samples. This will increase the precision and cost-effectiveness of genomics and molecular biology studies. Takara Bio USA Inc. is a US-based biotechnology company specializing in the development, manufacturing, and distribution of research reagents, instruments, and competent cells.

Major companies operating in the competent cells market are Thermo Fisher Scientific Inc., Avantor Inc., Agilent Technologies Inc., Sigma-Aldrich, Bio-Rad Laboratories Inc., QIAGEN N.V., Promega Corporation, GenScript Biotech Corporation, Takara Bio Inc., New England Biolabs Inc., TransGen Biotech Co. Ltd., HiMedia Laboratories Pvt. Ltd., Zymo Research Corporation, Lucigen Corporation, Meridian Bioscience Inc., Codex DNA Inc., OriGene Technologies Inc., SERVA Electrophoresis GmbH, SMOBIO Technology Inc., Yeastern Biotech Co. Ltd., Scarab Genomics LLC, Enzynomics Co. Ltd., NZYTech Lda., Gold Biotechnology Inc., Abyntek Biopharma S.L.

North America was the largest region in the competent cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the competent cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the competent cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Competent cells are bacterial cells that have been treated to become capable of taking up foreign deoxyribonucleic acid (DNA). These cells are crucial in molecular biology for cloning and transformation experiments, as they facilitate the introduction of genetic material into the cells. The main goal of using competent cells is to enable the uptake of foreign DNA during the transformation process.

The primary types of competent cells are chemically competent cells, electrocompetent cells, and ultracompetent cells. Chemically competent cells are prepared through chemical treatments that increase their membrane permeability, allowing DNA to enter more easily. These cells are utilized in various applications such as cloning, protein expression, and mutagenesis. They are employed by a range of end users including contract research organizations, pharmaceutical and biotechnology companies, and academic research institutions.

The competent cells market research report is one of a series of new reports that provides competent cells market statistics, including competent cells industry global market size, regional shares, competitors with a competent cells market share, detailed competent cells market segments, market trends and opportunities, and any further data you may need to thrive in the competent cells industry. This competent cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The competent cells market consists of sales of specialized competent cells, transformation kits, ready-to-use competent cells kits, and competent strain-specific cells. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.